5 Key Takeaways

• 1

  MIGS procedures experienced rapid growth after 2012, coinciding with FDA approval of iStent, but may slow due to new Medicare regulations.

• 2

  The annual number of glaucoma procedures for Part B Medicare beneficiaries averaged 307,878 from 1994 to 2023, with a peak in 1994.

• 3

  The 2023 proposed local coverage determination for MIGS raised the bar for medical necessity, likely reducing procedure growth.

• 4

  Emerging technologies like Voyager DSLT and mfPOP are expected to enhance glaucoma care and support MIGS recommendations.

• 5

  As the US population ages, the demand for glaucoma treatments will increase, but MIGS growth may be tempered by payer constraints.